Thematic

E

en.hdbuzz.net

Skyhawk reports encouraging 12-month results for oral Huntington’s disease drug SKY-0515 – HDBuzz

Read the original →

What this article backs

• Sky 0515 ↓ Mutant Huntingtin Protein

• Sky 0515 decreases Mutant Huntingtin Protein.

In its own words

Skyhawk reports encouraging 12-month results for oral Huntington's disease drug SKY-0515

Corroborated by

• N

  SKY-0515 Demonstrates Dose-Dependent Reductions in Mutant Huntingtin Protein in Phase 1 Update | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

  neurologylive.com · Sep 18, 2025 Standard

  Backs 2 claims

  • Sky 0515 ↓ Mutant Huntingtin Protein
  • Sky 0515 Dose Level ↓ Mutant Huntingtin Protein

  Read article →

More from en.hdbuzz.net

• Illustration E

  The Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130 – HDBuzz

  en.hdbuzz.net · Jun 17, 2026 Standard

  Backs 1 claim

  • Amt 130 Gene Therapy ✚ Fda Approval

  Read article →
• Illustration E

  Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam – HDBuzz

  en.hdbuzz.net · May 4, 2026 Standard

  Backs 1 claim

  • Votoplam ↓ Mutant Huntingtin Protein

  Read article →
• Illustration E

  Putting it in print: oral drug branaplam lowered huntingtin, but safety concerns halted development – HDBuzz

  en.hdbuzz.net · Feb 12, 2026 Standard

  Backs 2 claims

  • Branaplam ↓ Mutant Huntingtin Protein
  • Branaplam Safety Concerns ✕ Branaplam

  Read article →
• Illustration E

  A hitch in the stitch reveals why DNA sequence patterns matter in Huntington’s disease   – HDBuzz

  en.hdbuzz.net · Feb 9, 2026 Standard

  Backs 1 claim

  • Htt Gene Mutation ⚡ Neurodegeneration

  Read article →
• Illustration E

  The First Domino Falls: AMT-130 Gene Therapy Slows Huntington’s in Landmark Trial – HDBuzz

  en.hdbuzz.net · Sep 24, 2025 Standard

  Backs 2 claims

  • Gene Therapy ↓ Neurodegeneration
  • Gene Therapy ✚ Uniqure

  Read article →